Indication
In combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents.
Medicine details
- Medicine name:
- trifluridine tipiracil (Lonsurf)
- SMC ID:
- SMC2654
- Pharmaceutical company
- Servier Laboratories Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- 12 August 2024
- SMC meeting date:
- 02 July 2024
- Patient group submission deadline:
- 07 May 2024